Category: Peptide Q&A
-
Is there clinical or preclinical evidence linking tesamorelin’s GH-releasing activity to neuroprotective effects or cognitive improvement in aging or neurodegenerative conditions?
Is there clinical or preclinical evidence linking tesamorelin’s GH-releasing activity to neuroprotective effects or cognitive improvement in aging or ne
-
How does tesamorelin influence insulin sensitivity, glucose metabolism, and lipid profiles in patients with metabolic syndrome or HIV-related metabolic complications?
How does tesamorelin influence insulin sensitivity, glucose metabolism, and lipid profiles in patients with metabolic syndrome or HIV-related metabolic
-
What is the optimal dosing regimen for tesamorelin in treating visceral adiposity, and how does dosage affect GH pulsatility and IGF-1 levels?
What is the optimal dosing regimen for tesamorelin in treating visceral adiposity, and how does dosage affect GH pulsatility and IGF-1 levels?
-
What are the most common and serious adverse effects associated with long-term tesamorelin use, particularly regarding glucose metabolism and risk of acromegaly?
What are the most common and serious adverse effects associated with long-term tesamorelin use, particularly regarding glucose metabolism and risk of ac
-
How do the results of in vitro studies on 5-Amino-1MQ correlate with in vivo animal data, and what gaps remain in translational research?
How do the results of in vitro studies on 5-Amino-1MQ correlate with in vivo animal data, and what gaps remain in translational research?
-
What are the key biomarkers used to assess 5-Amino-1MQ’s biological activity in human trials, such as phospho-AMPK, NAD+ levels, or inflammatory cytokines?
What are the key biomarkers used to assess 5-Amino-1MQ’s biological activity in human trials, such as phospho-AMPK, NAD+ levels, or inflammatory cytokin
-
How does 5-Amino-1MQ compare to resveratrol in terms of AMPK activation potency, bioavailability, and longevity effects in model organisms?
How does 5-Amino-1MQ compare to resveratrol in terms of AMPK activation potency, bioavailability, and longevity effects in model organisms?